Crucial Commission studies to shape new regulatory practices
This article was originally published in Clinica
Executive Summary
The European Commission's agenda for the remainder of 2007 includes several studies critical to tightening up the EU's medtech regulatory act. Items under the spotlight for the next few months will include: reprocessing, counterfeiting, vigilance and the overlap with the Advanced Therapies Medicinal Products Regulation.